Merck joins forces with Isomorphic Labs to harness AI for next-generation cancer drugs
By: IPP Bureau
Last updated : November 20, 2026 10:54 am
Merck is joining forces with AI-driven drug discovery company Isomorphic Labs in a strategic research collaboration aimed at designing new cancer-fighting drugs, bringing artificial intelligence and advanced molecular research together to tackle a key oncology target.
The collaboration will combine Isomorphic Labs’ proprietary AI-powered drug design engine with Merck’s extensive proprietary data resources and deep drug discovery expertise to identify potential small-molecule therapeutic candidates against an oncology target of strategic importance.
Under the agreement, Isomorphic Labs will use its proprietary Drug Design Engine (IsoDDE) to conduct computational predictions and generate molecular designs, incorporating selected high-quality proprietary datasets provided by Merck.
Merck will take charge of the subsequent preclinical and clinical development of any resulting candidates, along with their manufacturing and commercialization.
The deal also includes a financial package for Isomorphic Labs comprising an upfront payment, milestone payments tied to research, development, regulatory and commercial achievements, and tiered royalties on net sales. The AI drug discovery company will also have the option to co-fund development activities in exchange for higher royalty payments.
“The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” said George Addona, senior vice president and head of discovery, preclinical development and translational medicine, Merck Research Laboratories.
“By combining Merck’s substantial internal data capabilities and discovery expertise with Isomorphic Labs’ powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster.”
For Isomorphic Labs, the partnership represents an opportunity to deploy its AI capabilities against a challenging oncology research programme, leveraging predictive and generative technologies to advance drug discovery.
“Through this collaboration with Merck, we will apply our world-leading drug design engine to unlock significant discovery progress,” said Sarah Skerratt, chief research officer, Isomorphic Labs.
“By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies’ shared commitment to innovation for the benefit of patient populations with unmet needs.”
The partnership underscores the growing role of artificial intelligence in pharmaceutical research, where advanced computational models, proprietary biological datasets and established drug development capabilities are increasingly being combined to tackle complex diseases.
By bringing together Isomorphic Labs’ AI-driven molecular design platform and Merck’s drug discovery and development expertise, the companies aim to accelerate the identification of promising therapeutic candidates and potentially open new avenues for cancer treatment.